12 results
20-F
2022 FY
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Aug 22
Annual report (foreign)
4:20pm
, clarity and transparency on the de novo classification process. In January 2021, it also published a final guidance entitled “Requests for Feedback … III Designation),” and in December 2018, the FDA published a proposed rule which if finalized is intended to provide structure, clarity and transparency
424B4
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
21 Jul 22
Prospectus supplement with pricing info
10:01am
structure, clarity and transparency on the de novo classification process. In January 2021, it also published a final guidance entitled “Requests … published a proposed rule which if finalized is intended to provide structure, clarity and transparency on the de novo classification process
F-1/A
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
24 Jun 22
Registration statement (foreign) (amended)
9:47pm
is intended to provide structure, clarity and transparency on the de novo classification process. In January 2021, it also published a final guidance
F-1/A
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
24 Jun 22
Registration statement (foreign) (amended)
8:21am
),” and in December 2018, the FDA published a proposed rule which if finalized is intended to provide structure, clarity and transparency on the de … if finalized is intended to provide structure, clarity and transparency on the de novo classification process. In January 2021, it also published a final
F-1/A
rh3c2ypup pt
21 Jun 22
Registration statement (foreign) (amended)
6:26am
F-1/A
2pbj31635gdixwo7nxv
6 Jun 22
Registration statement (foreign) (amended)
6:13pm
F-1/A
dxkhq31dbva
11 May 22
Registration statement (foreign) (amended)
3:11pm
F-1/A
2p1ctz5ye7k 707d
22 Apr 22
Registration statement (foreign) (amended)
6:09pm
F-1
k1v9a
18 Mar 22
Registration statement (foreign)
3:50pm
DRS/A
le6xr
17 Feb 22
Draft registration statement (amended)
12:00am
DRS
cir n87sq7
27 Dec 21
Draft registration statement
12:00am
- Prev
- 1
- Next